1. Introduction
Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the aged population. In 2005, it was estimated that 24.3 million people world-wide suffer from AD (Ferri et al., 2005) . In the US alone, $237 billion is spent annually to provide care for the 5 million Americans suffering from AD (Alzheimer's Association, 2009). Given that age is the most important risk factor to develop AD, the number of patients is expected to rise dramatically in the coming years with each year 4.6 million new cases worldwide. Currently, there is no effective therapy to prevent, delay or reverse the disease process of AD (Roberson and Mucke, 2006) .
In postmortem brain tissue of AD patients, numerous extra-and intracellular deposits of misprocessed, misfolded and aberrant proteins are found, such as amyloid-b (Ab), hyperphosphorylated tau and ubiquitinated proteins, which accumulate during the course of the disease (Bertram and Tanzi, 2008; Hol et al., 2005; LaFerla et al., 2007) . The genetic familial forms of AD (FAD), comprising a few percent of all demented cases, indicate that misprocessing of amyloid precursor protein (APP) and/or altered regulation of intraneuronal amyloid is involved in AD pathogenesis (Roberson and Mucke, 2006) . These familial forms have further provided important information on the regulation of APP processing by presenilins (PSEN1 and PSEN2, also often referred to as PS1 and PS2) and their role in amyloid plaque formation. However, in the large population of the more common, non-inheritable ''sporadic'' cases of AD, the main risk factors are age and the ApoE-genotype (Bu, 2009 ).
The a-helical Ab peptide, the main constituent of AD plaques, is cleaved from the type I membrane glycoprotein APP by the consecutive activity of b-and g-secretases, resulting in the secretion of Ab into the extracellular space. Different isoforms of Ab are produced varying in length between 38 and 42 amino acids, each having distinct aggregation characteristics (Haass and Selkoe, 2007) . Also shorter C-terminal truncated Ab fragments have been identified, of which Ab isoforms Ab 1-14 to Ab 1-16 result from APP processing by b-secretase and a-secretase (Blennow et al., 2010; Portelius et al., 2009 ). In AD, the levels of Ab 42 are increased and the ratio of Ab 42 / Ab 40 is elevated. When extracellular Ab levels reach a threshold concentration, Ab will undergo conformational changes and aggregate. Especially Ab 42 has a high propensity to aggregate and form extracellular deposits in the brain of AD patients. In the amyloid hypothesis of AD, accumulation of Ab is seen as the main underlying cause of AD pathology (Hardy and Selkoe, 2002) . The current consensus among Alzheimer researchers is that the oligomeric forms of Ab are the real culprit (Haass and Selkoe, 2007; Lansbury and Lashuel, 2006) , while intraneuronal Ab accumulation has attracted considerable interest as well Wirths et al., 2009) . In that sense, formation of extracellular amyloid plaques may, in fact, represent a defense mechanism of the brain to eliminate toxic Aboligomers from the cell.
Neurogenesis in Alzheimer's disease
Given the profound memory deficits and prominent hippocampal pathology in AD, the role of adult neurogenesis, a process occurring selectively in the adult hippocampus and ventricular zone, has attracted considerable attention in the AD field. In contrast to the general post-mitotic state of the adult nervous system, new cell birth and ongoing neurogenesis does occur in restricted regions of the brains of adult rodents and primates, including humans. The identification of these stem cells in the adult brain has nurtured the hope to recruit these cells to facilitate repair of damaged neural tissue.
Adult neurogenesis occurs in two distinct locations; the subventricular zone (SVZ) and subgranular zone (SGZ), located in the lateral ventricle wall and hippocampal dentate gyrus (DG), respectively (Ming and Song, 2005; Zhao et al., 2008) while in a few other brain regions limited cytogenesis and/or neurogenesis may occur under specific conditions (Gould, 2007) . The SVZ and SGZ are unique zones as they contain neural stem cells (NSCs) that retain the capacity to proliferate, migrate, and differentiate into new, fully functional neurons in a mature environment. The addition of newly born neurons to an existing circuit by means of adult neurogenesis represents a novel and unique form of structural plasticity that not only allows adaptation for the longer term, but also may constitute an endogenous cell replacement mechanism. As such, adult neurogenesis may determine ''neural reserve'' in selective brain regions (Kempermann, 2008; Zhao et al., 2008) .
Neurogenesis occurs throughout the lifespan of many bird, rodent and primate species, indicating an important role that is conserved throughout evolution (Gould, 2007) . Numerous studies have further identified factors that modulate production and survival of the newborn hippocampal neurons during adulthood; e.g. voluntary exercise, anti-depressant treatment and environmental enrichment increase the number, survival and in vivo fate of newborn cells, whereas (early) stress exposure or aging decreases neurogenesis (Heine et al., 2004; Kempermann et al., 2002; Kuhn et al., 1996; Leuner et al., 2007; Lucassen et al., 2010a,b; Marlatt and Lucassen, 2010; Oomen et al., 2007 Oomen et al., , 2010 Rao et al., 2006) .
Although the number of new neurons directly incorporated into the adult or aged DG may be low, this ongoing phenomenon holds a potential for adaptation, as the NSCs in the adult brain are multipotent and can differentiate into neurons, astrocytes or oligodendrocytes in vitro Sanai et al., 2004) . Interestingly, hippocampal sprouting, cyto-and neurogenesis in adult or aged individuals is potently increased in response to various types of hippocampal insults or damage, as e.g. occurs during ischemia, epilepsy or head injury, but the effects on hippocampal circuit properties and on the progress of AD are poorly understood (reviewed by Castellani et al., 2007; Kuhn et al., 2007; Marlatt and Lucassen, 2010) . Assuming that a neurogenic response to damage in human brain could one day be utilized, neurogenesis may constitute a potential endogenous mechanism to replace lost or damaged cells, provided that also the affected local environment can be made ''permissive'' to these new cells.
Regarding AD, it has e.g. been shown that Ab itself is toxic to neural progenitors (Donovan et al., 2006; Haughey et al., 2002a; Jin et al., 2004a; Li and Zuo, 2005; Lopez-Toledano and Shelanski, 2004) . In addition, changes in hippocampal cytogenesis and neurogenesis have been reported in AD brain and in selective mouse models for dementia with the direction of the effect depending on the development and progression of the pathology (Boekhoorn et al., 2006; Ekonomou et al., 2010; Jin et al., 2004b; Kuhn et al., 2007; Li et al., 2008; Thompson et al., 2008; Yu et al., 2009 ).
Studies on neurogenesis in AD brain are limited and hampered by technical difficulties. In 2004 it was reported that hippocampal neurogenesis in a cohort of old AD cases was increased, based mainly on the increased expression of doublecortin (DCX) and PSA-NCAM by Western blot analysis (Jin et al., 2004b) . Also proliferation, as measured by the expression of cell proliferation marker Ki-67, was found to be significantly increased in hippocampi of presenile AD cases, but this was found to be restricted to astrocyte-rich regions and not seen in e.g. the neuronal cell layer of the DG (Boekhoorn et al., 2006) . A third study has found dramatically decreased expression of microtubule associated proteins in the DG, indicating that an increased cell proliferation in the DG in AD is not translated into the generation of new neurons, a finding providing some resolution of the prior conflicting reports as also corroborated by some animal studies (Ermini et al., 2008; Yu et al., 2009) . Since a subset of astrocytes is known to be neural progenitors, the observation of an increase in astrocyte proliferation might possibly reflect an induction of neurogenesis, while also the expression of the astrocyte marker GFAP in a subset of DCX-positive cells in the cortex of patients suffering from neurodegenerative disease (Verwer et al., 2007) and related changes in vascular dementia (Ekonomou et al., 2010) are interesting in this respect.
Astrocytes play a critical part in the maintenance of neurogenesis; they provide trophic and metabolic support to neurons; astrocyte number and complexity distinguish the human brain from other mammals, astrocytes are known to play an important role in SGZ neurogenesis (Doetsch et al., 1999; Oberheim et al., 2006) and factors secreted by activated astrocytes have been identified that modulate neural progenitor cell (NPC) differentiation (Barkho et al., 2006; Song et al., 2002) . In vivo, SVZ neurogenic astrocytes migrate via the rostral migratory stream (RMS) into the olfactory bulb to form new neurons (Doetsch et al., 1999; Garcia et al., 2004) . Importantly, these cells can also migrate into a damaged brain area and differentiate into new neurons outside the olfactory bulb (Yamashita et al., 2006) . Recent observations show that astrocytes also in other brain areas can become neurogenic (Buffo et al., 2008; Walton et al., 2006) , further highlighting their potential as an important therapeutic target for various neurological disorders. In the human SVZ, in analogy with the mouse brain, an astrocytic ribbon is present that contains neurogenic cells (Sanai et al., 2004) . Curtis et al. (2007) later demonstrated that humans do have an RMS, which contains cells which are positive for the GFAP isoform GFAP-d, which is associated with neural stem cell properties (Roelofs et al., 2005; van den Berge et al., 2010) .
The generation of mouse models for several aspects of AD pathology over the past decades has significantly contributed to our understanding of genotype-phenotype interactions and causeand-effect issues. These models have been indispensable in the development of therapeutic strategies. So far, transgenic AD models have focused primarily on pathological disease markers and behavioral alterations, and neurogenesis has been evaluated only to a limited extent. The studies available on this topic vary considerably, and either increases or decreases in proliferation and neurogenesis have been reported, that appear to depend on the age of the mice, the phase of neurogenesis under study, the promoter used and their genotype. Notably, these mice all overexpress FAD mutant PSEN or APP. Both these proteins are implicated in Notch signaling Handler et al., 2000) and neurogenesis may therefore be affected directly via this pathway. Effects of loss of Psen expression or mutant PSEN overexpression on NPCs and neurogenesis in mice (Section 3) and zebrafish (Section 4) will be discussed in this review. For an overview of studies conducted on neurogenesis in other AD mouse models, we refer to some recent reviews on this topic (Ermini et al., 2008; Kuhn et al., 2007; Lazarov and Marr, 2010; Marlatt and Lucassen, 2010; Thompson et al., 2008 ).
Presenilins
PSEN is most well known as part of the g-secretase complex, but this versatile protein also participates in mechanisms regulating cellular proliferation. Interest in g-secretase and its role in the generation of diverse Ab species with different propensities to aggregate has led to numerous studies on the function of PSEN in vitro and in transgenic mice expressing (mutant) human PSEN. PSEN1 and PSEN2 are membrane spanning proteins, which are endo-proteolytically cleaved into two stable fragments, an N-terminal fragment (NTF) and C-terminal fragment (CTF) (Fig. 1) . Two separate PSEN genes are identified in human, PSEN1 and PSEN2, which show a high sequence homology. Autosomal dominant mutations in either of the PSEN genes are causative for the hereditary form of AD, FAD (De Strooper, 2007) .
PSENs are the catalytic subunit of the proteolytic g-secretase complex, a protease performing intra-membrane cleavage of many different type 1 transmembrane proteins. Two highly conserved aspartates in transmembrane domain 6 and 7 form the core of the catalytic site (Spasic and Annaert, 2008) (Fig. 1) . Besides PSEN, the g-secretase complex consists of three additional components; nicastrin, anterior pharynx defective 1 (Aph-1) and presenilin enhancer 2 (Pen-2 or Psenen) (De Strooper, 2003) .
The g-secretase complex cleaves many substrates, of which APP and Notch are the most well known. Consecutive cleavage of APP by b-and g-secretases results in the formation of Ab peptides, which form the main component of the AD plaques (Parks and Curtis, 2007; Selkoe and Wolfe, 2007) (Fig. 2) . A physiological role for Ab 42 in mediating synaptic plasticity has been suggested (Balducci et al., 2010; Shankar et al., 2008) , and the cellular prion protein can act as an Ab-oligomer receptor (Lauren et al., 2009 ).
Furthermore, a function for the APP derivative N-APP, formed by bsecretase cleavage of APP followed by further cleavage by as yet unknown proteases, has been shown in neuronal pruning during development (Nikolaev et al., 2009) . Besides the release of Ab peptides by the cleavage of APP at the g-site, the APP intracellular domain (AICD) is released by g-secretase mediated e-cleavage of APP (Fig. 2) . AICD is thought to regulate gene transcription of several putative target genes (Cao and Sudhof, 2001) , although its role in the pathophysiology of AD is debated (Muller et al., 2008) . Recently, it has been shown that AICD-overexpressing transgenic Fig. 1 . Presenilin structure. Schematic representation of human PSEN1 membrane topology. PSEN1 has ten hydrophobic domains (in purple) with nine proposed transmembrane domains (TMD) (Spasic and Annaert, 2008) . PSEN undergoes endoproteolytic cleavage within hydrophobic domain 7 forming the stable NTF and CTF fragments. The two aspartate residues in TMD6 and TMD7 making up the PSEN1 catalytic site are shown in red triangles.
mice show hyperphosphorylation and aggregation of tau (Ghosal et al., 2009) , implying that AICD can contribute to AD pathology independent of Ab.
Analogous to APP cleavage, Notch processing by g-secretase releases the Notch intracellular domain (NICD), which then translocates to the nucleus where it activates Notch-responsive genes (Selkoe and Kopan, 2003) (Fig. 2) . However, the role of PSEN extends beyond the proteolytic processing of these two wellstudied substrates, as there are many other proteins known to be processed by PSEN/g-secretase, including APP homologues APLP1 and APLP2 and the Notch ligands Delta and Jagged (Parks and Curtis, 2007) . PSEN is also involved in g-secretase-independent processes, including ER calcium homeostasis (Tu et al., 2006) , lysosomal proteolysis and Wnt signaling (Boonen et al., 2009) . As Wnt signaling has been implicated in various aspects of AD pathogenesis, altered PSEN activity might contribute indirectly to disease progression via this signaling pathway.
Presenilins in neurogenesis
PSEN1 is a key regulator in Notch and Wnt signaling and is responsible for the developmental maturation of glia and neurons. The protein is prominently expressed in the embryonic nervous system Moreno-Flores et al., 1999) and in NPCs in the adult brain of mice (Wen et al., 2002a) . Notch signaling is essential for correct neuronal differentiation during embryogenesis. Notch target genes in the nervous system include the HES (hairy and enhancer of split) family genes HES1 and HES5, belonging to the basic helix-loop-helix family of transcription factors. Notch is among others involved in the maintenance of the neural progenitor pool and cell fate decisions during embryogenesis (Louvi and Artavanis-Tsakonas, 2006) . Also in the adult nervous system, Notch pathway components are expressed in differentiated neurons and play a role in neural processes, including brain plasticity (Lathia et al., 2008) .
In brains of sporadic AD patients, the expression of Notch and Notch ligand delta-like protein 1 is upregulated , but there is no direct evidence demonstrating that FAD mutations in PSEN1 can influence the proliferation or survival of NPCs in humans. As g-secretase mediates cleavage of Notch and release of the NICD fragment, impaired Notch signaling in AD could contribute to alterations in the NPC compartment ultimately affecting neurogenesis. As discussed in this review, animal models of (FAD) PSEN have greatly improved our understanding of the role of PSEN in AD and the involvement in neurogenesis.
Various proteolytic derivatives of APP can influence NPCs and neurogenesis. APP is e.g. expressed in human embryonic stem cells (hESC), and it has been shown that differential cleavage of APP by alternative secretase activity affects differentiation into NPCs, whereas the non-amyloidogenic pathway suppresses hESC proliferation and promotes NPC differentiation (Porayette et al., 2009 ).
In non-pathological situations, APP is mostly cleaved by asecretase, thereby releasing the N-terminal soluble sAPPa fragment. sAPP can stimulate the proliferation of NPCs in the SVZ of the adult mammalian brain (Caille et al., 2004) and increase the differentiation of human NSCs in vitro (Kwak et al., 2006) . In contrast with these data, sAPP has also been shown to be involved in activating the death receptor DR6, leading to neuronal cell death (Nikolaev et al., 2009) . Contradictory data are available for Ab 40 and Ab 42 peptides, as they can induce neurogenesis and stimulate neuronal differentiation in various neural stem/progenitor cell culture systems (Chen and Dong, 2009; Lopez-Toledano and Shelanski, 2004; Sotthibundhu et al., 2009 ), but also adverse effects have been reported on cultured NPCs (Haughey et al., 2002b) . Recently, APP signaling, through the release of AICD, has been shown to negatively modulate neurogenesis by promoting NSC fate and maintenance . Although the AICD/Fe65 transcriptional gene targets involved in regulating neurogenesis are not yet known, this study stresses the important role for APP signaling in regulating the NSC compartment and neurogenesis. Should PSEN activity be altered in (F)AD, abnormal processing of APP might affect the generation of AICD which in turn can modulate neurogenesis already during early stages of central nervous system (CNS) development.
Presenilin FAD mutations
As yet, over 170 autosomal mutations in the PSEN1 gene and more than 10 mutations in PSEN2 have been identified, which lead to early onset FAD. In the APP gene, over 25 causative mutations are identified for FAD (http://www.molgen.ua.ac.be/ADMutations). The majority of PSEN1 mutations are missense mutations resulting in single amino acid changes in the PSEN1 protein. The mutations are spread throughout the whole length of the PSEN1 protein and exert their effect in a dominant negative manner. Many FAD mutations increase the ratio of the more fibrillogenic form of Ab, the Ab 42 peptide, over Ab 40 , which is interpreted as a gain of toxic function. However, this altered ratio can also be derived from a decrease in Ab 40 formation, accompanied by increased accumulation of the g-secretase substrate APP CTF (Bentahir et al., 2006; Kumar-Singh et al., 2006) . Therefore, biochemical loss-of-function of PSEN can result in a gain-of-toxic-function of the APP gene through decreased or alternative g-secretase cleavage, favoring the generation of the Ab peptides of 42 amino acids in length. Although the underlying causes leading to sporadic AD and inherited FAD likely differ, they are indistinguishable in terms of neuropathological hallmarks (De Strooper, 2007; Wolfe, 2007) . New insights into PSEN function using PSEN FAD model systems may thus also provide clues regarding the role of PSEN in sporadic AD. According to the amyloid hypothesis of AD, Ab accumulation is the main cause underlying AD neurodegeneration (Hardy, 2009; Hardy and Selkoe, 2002) . However, in view of the existence of tauopathies, amyloid pathology alone is not a prerequisite for developing dementia. Moreover, unlike neurofibrillary tangle pathology, amyloid plaque load poorly correlates with the cognitive status of AD patients (Ingelsson et al., 2004; Perrin et al., 2009) . Also in mouse models overexpressing FAD mutant APP, substantial neurodegeneration is generally absent although prominent accumulation of Ab in plaques is present. Furthermore, many functional deficits in LTP and cognition, e.g., already occur long before the plaque pathology develops (Elder et al., 2010a; Gotz and Ittner, 2008; Gotz et al., 2009; Muyllaert et al., 2006) .
In the ''presenilin hypothesis'' of AD, Shen et al. advocate that loss-of-function of PSEN protein is a central event in AD pathogenesis (Shen and Kelleher, 2007) . Loss of Psen activity in a conditional knockout mouse model with inactivation of Psen1 and Psen2 in postnatal neurons shows age-related neurodegeneration, including synaptic loss, neuronal death and tau hyperphosphorylation, without Ab formation (Saura et al., 2004) . Regarding the FAD mutations in PSEN, many of them are regarded as loss-offunction mutations towards g-secretase activity (De Strooper, 2007) . Reduced expression of PSEN due to polymorphisms in the PSEN promoter has also been regarded as a risk factor for sporadic AD (Theuns et al., 2003) . PSEN1 expression is regulated on a transcriptional level by histone (de-)acetylation and by various transcription factors. As levels of PSEN/g-secretase activity might be an important factor in the development of AD pathology, modulation of the transcription factors which regulate PSEN expression can potentially be used as therapeutic strategy for AD treatment (Das, 2008) .
Although the presenilin hypothesis is consistent with specific genetic observations, mouse models without a functional Psen do not recapitulate all features of AD pathology, and lack e.g. neurofibrillary tangles or Ab plaques. Nevertheless, this alone does not preclude PSEN from playing an important role in AD pathology. Lowering PSEN activity with general broad spectrum gsecretase inhibitors can potentially lower Ab levels and alleviate plaque pathology (also see Section 3.4). However, decreasing gsecretase activity might at the same time be detrimental to other physiological processes. Employing selective g-secretase inhibitors that target APP processing, but do not alter cleavage of other substrates like Notch, would circumvent effects on Notch-related developmental processes and may thus provide a promising therapeutic approach (Bergmans and De Strooper, 2010; Selkoe and Wolfe, 2007) . Understanding the physiological role of PSEN in a normal state, as well as in AD, is therefore of great importance. As PSEN is thought to have a broad array of functions in many cellular processes, it is conceivable that loss of PSEN function may affect many intracellular pathways. In this review, we will further focus on animal models recapitulating loss of Psen function or expressing FAD mutated PSEN and how this affects neuronal differentiation and neurogenesis during embryonic development and in adult tissue.
Presenilin mouse models
Mouse models have provided important insights in the physiological role of PSEN, as well as in their role in neurodegenerative disease. In mice, Psen1 is expressed in the brain during embryogenesis and in adulthood. Already at the earliest stages of development, Psen1 and Psen2 proteins are present in the preimplantation embryo where they are critical for the regulation of cell division (Jeong et al., 2000) . Psen1 and Psen2 mRNA expression is abundant in neuro-epithelial cells during early development and in the NPC containing ventricular zone during later stages of development. In adult mice, the expression of Psen mRNA is diminished but remains to be present mainly in neurons of the cortex, hippocampus and cerebellum and, to a lower extent, glial cells (Berezovska et al., 1997; Lee et al., 1996) . Psen1 is expressed in the NPCs in the subgranular zone of the DG in adult mouse hippocampus, suggesting a role for Psen1 in neurogenesis. These Psen1 expressing cells show co-localization with the NPC marker nestin, further identifying these cells as NPCs in the adult brain (Wen et al., 2002a) . The murine Psen expression patterns are quite similar to human, where Psen1 and Psen2 mRNA are expressed in brain tissue during development as well as in adulthood. As in mice, the hippocampal and cerebellar cell layers show increased expression of Psen, and Psen1 transcripts are found in white matter, suggesting expression in glial cells Suzuki et al., 1996) .
Presenilin knockout mouse models

Presenilin 1 mutant mice
To better understand Psen function, Psen1 and Psen2 knockout mouse models have been generated. An overview of the Psen1 and Psen2 (double) knockout mouse lines and their phenotypes is given in Table 1 . Psen1À/À mice show perinatal lethality, gross axial skeleton deformations, intracranial hemorrhaging and CNS abnormalities, while also somite segmentation and differentiation defects are present (Shen et al., 1997; Wong et al., 1997) . This phenotype to some extent resembles a Notch1À/À phenotype, which shows skeletal and somite defects as well (Conlon et al., 1995) . In Psen1À/À embryos, Notch1 mRNA and Notch ligand deltalike1 (Dll1) mRNA were reduced (Wong et al., 1997) , however, these results could not be confirmed in later studies (Handler et al., 2000; Koizumi et al., 2001) . In Psen1À/À mice, neural development abnormalities are further present from day E12.5 onwards and lead to severe symmetrical loss of neurons and NPCs in the ventricular zones and SVZ of the ventro-lateral region and a thinner cortical plate, all indicating decreased neurogenesis and disturbances in hippocampal DG formation (Shen et al., 1997) . Data from these Psen1À/À mouse models indicate that Psen1 plays a critical role in neurogenesis during mouse development.
The observed decrease in NPCs during early development is caused by premature differentiation of the NPCs into post-mitotic neurons in the telencephalon and diencephalon, and leads to a reduced size of the ventricular zone. Cell proliferation and apoptosis are not affected in this cell population. Also, cortical neuronal migration is altered in Psen1À/À mice, leading to disrupted cortical layer formation. These effects are mediated by a downregulation of the Notch signaling pathway during neuronal differentiation (Handler et al., 2000) . Also in a different Psen1À/À line, increased proliferation of the neural progenitors, premature neuronal differentiation and aberrant neuronal migration were observed (Yuasa et al., 2002) . In an extensive study of CNS morphogenesis and neuronal migration in Psen1À/À mice, the defects in neuronal migration were found to occur widespread throughout the CNS. In the mid/hindbrain morphogenesis defects were present, indicating that loss of Psen1 function affects neuronal development in many brain regions (Louvi et al., 2004) . In Psen1 knockout mice, also the number of Cajal-Retzius neurons is reduced compared to control littermates, leading to cortical dysplasia . This effect occurs in a non-cell-autonomous manner, as Nestin-Cre conditional knockout mice with Psen1 inactivation only in CNSderived cells, have normal numbers of Cajal-Retzius neurons. This suggests that loss of Psen1 in non-neuronal tissue, possibly in meningeal cells, underlies the Cajal-Retzius neuron loss (WinesSamuelson et al., 2005) .
The observed Psen1À/À embryonic lethality can be rescued by crossing these mice to a transgenic line expressing human PSEN1 under the control of the Thy-1 promoter, which not only drives expression mainly in the CNS in adult mice, but also induces ubiquitous low levels of expression during embryonic development. Thy-1 mediated expression of human PSEN1 can completely rescue the intracranial hemorrhages as well as the neuronal defects (Qian et al., 1998) . Also a transgenic line expressing human PSEN1 under the mouse prion promoter, driving transgene expression from E8.5 onwards, rescues the developmental phenotype of Psen1À/À mice (Davis et al., 1998) . These results indicate that PSEN function is highly conserved between mouse and human. In a nestin-driven human PSEN1 transgenic line, embryonic lethality remained, but the cortical lamination defects, cerebral hemorrhages and cell migration defects observed in Psen1À/À mice could be rescued. In contrast, neuronal expression of PSEN1 did not rescue any aspect of the Psen1 knockout phenotype (Wen et al., 2005) . Together, this suggests that expression of Psen1 in the NPCs plays an important role in neural development.
Presenilin 2 mutant mice
In contrast to Psen1 knockout mice, Psen2À/À mice are viable and fertile and show only a mild pulmonary phenotype without CNS abnormalities (Donoviel et al., 1999; Herreman et al., 1999) . The milder phenotype in Psen1 knockout mice compared to Notch pathway mutant mice suggests that Psen2 can partially compensate for the loss of Psen1. Indeed, in double Psen1/2 knockout mice, the Psen1À/À phenotype is aggravated, including embryonic lethality at E9.5, ventral neural tube disorganization and lack of somite differentiation (Donoviel et al., 1999; Herreman et al., 1999) . Ectopic expression of Notch ligand Dll1 and a complete downregulation of Notch target gene Hes5 shows that knockdown of both Psen1 and Psen2 results in a loss of Notch signaling. The more severe phenotype in the double knockout model suggests that Psen1 and Psen2 are to some extent functionally redundant. However, mice with a loss of a single copy of Psen1 in a Psen2À/À background are phenotypically normal, whereas heterozygozity for Psen2 in a Psen1À/À context clearly aggravates the Psen1 Handler et al. (2000) and Koizumi et al. (2001) Symmetric NPC and neuron loss in the ventricular and sub-cortical zones, impaired neurogenesis, less distinct dentate gyrus formation Shen et al. (1997) Premature neuronal differentiation of the NPCs
Handler et al. (2000) and Yuasa et al. (2002) knockout phenotype, showing that Psen1 and Psen2 also have nonidentical functions in mice (Donoviel et al., 1999) .
Conditional presenilin knockout mouse models
The perinatal lethality of Psen1À/À mice precludes the analysis of adult phenotypes, therefore conditional Psen1 knockout mouse models were developed. Selective Psen1 ablation in the forebrain using the Cre/loxP system with Cre being expressed under the CamKIIa promoter, eliminated Psen1 expression in neurons in the hippocampus and neocortex from the third postnatal week onwards. These conditional knockout mice are viable and do not show gross phenotypic abnormalities or deficits in hippocampal synaptic transmission. As Psen1 is functional in the g-secretase complex, Ab formation resulting from APP cleavage by g-secretase is decreased, whereas a-secretase and b-secretase cleavage are unaffected and APP CTFs resulting from b-secretase cleavage accumulate in the cortex (Feng et al., 2001; Yu et al., 2001) . Similar results are found in a conditional Psen1À/À model with postnatal neuronal deficiency of Psen1 under the Thy-1 promoter (Dewachter et al., 2002) .
Surprisingly, expression of the Notch target genes Hes1, Hes5 and Dll1 is not affected in the cortex of these conditional knockout mice (Dewachter et al., 2002; Yu et al., 2001) , in contrast to the altered expression of the Notch targets in Psen1À/À mice (Handler et al., 2000) . This could reflect a difference in the role of Psen1 in Notch processing between developmental and adult stages, or alternatively, Psen2 might be able to compensate for Psen1 inactivation in adult brain better than during embryogenesis. Conditional Psen1 knockout mice show no differences in total neuron number or in newborn neurons and glia in the DG of the hippocampus in adult brain. However, environmental enrichmentinduced neurogenesis in the DG is suppressed, indicating a role for Psen1 in the regulation of adult hippocampal neurogenesis (Feng et al., 2001) . Although in this paper, neurogenesis was implicated in clearance rather than consolidation of memories, the decrease in enrichment-induced neurogenesis was not associated with a severe cognitive phenotype in these mice (Feng et al., 2001 ). In the model of Yu et al. (2001) , Psen1 conditional knockout mice were mildly impaired in a watermaze paradigm for spatial learning and memory.
In a mouse line with progenitor cell-specific conditional knockdown of Psen1 expression, Psen1 is inactivated in nestin positive NPCs and NPC-derived neurons and glial cells. Inactivation of Psen1 expression is present from E10.5 onwards. These mice are viable and survive for 2-3 months, allowing to study the role of Psen1 in late embryonic development and postnatal stages. The nestin-Psen1 conditional knockout mice exhibit premature differentiation of NPCs similar to the Psen1À/À mice. Neuronal migration of late-born neurons and cortical lamination is disrupted, possibly caused by a progressive reduction in the number of radial glia (Wines-Samuelson et al., 2005) .
As conventional double Psen1/2 knockout mice are embryonically lethal, the role of presenilins was further studied in conditional double Psen knockouts, generated by crossing forebrain-specific Psen1 knockout mice onto a Psen2À/À background. Conditional double knockout of both presenilins causes a more severe phenotype than seen in single conditional Psen1À/À mice. These mice are viable and fertile, but start to develop abnormal behavior from 10 months onwards, accompanied by forebrain degeneration and enlargement of the ventricles. Neuronal atrophy, tau hyperphosphorylation, astrogliosis and increased apoptosis are also found in these mice (Feng et al., 2004) . In a similar model, a mild impairment in hippocampal memory and synaptic plasticity is already observed at 2 months of age, which increases in severity during aging, and an age-dependent neurodegeneration is observed as also seen before (Saura et al., 2004) . These changes in plasticity are derived through a pre-synaptic mechanism, as shown in a conditional Psen double knockout in which Psen expression is specifically repressed in CA3 pre-synaptic neurons in the hippocampus ).
The progressive neuron-loss observed in the conditional Psen double knockout is preceded by an increased number of degenerating neurons already at 2 months of age, whereas the apoptotic cell death resulting in volume loss appears to be more pronounced in the cortex than in the hippocampus (Wines-Samuelson et al., 2010) . By crossing the nestinconditional Psen1 knockout (Wines-Samuelson et al., 2005) on a Psen2À/À background, Psen expression is inactivated in all NPCs. This leads to perinatal death and a marked decrease in NPCs after E13.5, resulting from a premature cell-cycle exit of the neural precursors and differentiation into neurons. Together, these data show that Psens are required for NPCs to remain in the cell cycle and for the expansion of the neural progenitor pool (Kim and Shen, 2008) .
Presenilin FAD mouse models
To study the effects of PSEN FAD mutations, transgenic mice have been developed that express human PSEN with a FAD mutation on a wild-type or a Psen knockout background. As ''PSEN1'' is often referred to as ''PS1'' in transgenic AD mouse lines, we will use ''PS1'' when directly referring to these AD mouse models in this review.
Expression of human FAD mutant PSEN1 or PSEN2 in mice does not cause the characteristic neuropathology found in AD patients, and amyloid plaques or neurofibrillary tangles are e.g. absent. However, these models do have elevated levels of the more amyloidogenic Ab 42 species without clear effects on Ab 40 (Huang et al., 2003; Oyama et al., 1998; Sudoh et al., 1998; Sun et al., 2005; Wen et al., 2004) . PSEN knock-in mice (PS1-I213T/KI) also display a selective increase of Ab 42 (Nakano et al., 1999) . Despite the lack of plaques, PSEN FAD mice do show a range of pathological changes: age related neurodegeneration (PS1-L286V and PS1-M146L models), altered spine density and morphology (PS1-A246E, PS1-M146L, PS1-L286V), vascular pathology (PS1-M146V, PS1-P117L), abnormal tau phosphorylation (PS1-I213T/KI, PS1DE9), reduced fast axonal transport, and age-dependent changes in longterm potentiation (PS1-M146L/KI, PS1-L286V, PS1-A246E, PS1DE9) are described. Moreover, several studies have found an increased sensitivity for excitotoxicity which has been attributed to an enhanced release of calcium from intracellular stores (Guo et al., 1999; Schneider et al., 2001) . PSEN mutations accelerate plaque formation in double transgenic lines expressing both PSEN FAD and APP FAD genes. For reviews related to the pathological effects of PSEN FAD mutations see reviews by De Strooper (2007) and Elder et al. (2010b) .
Proliferation and neurogenesis in presenilin FAD models
Since neurogenesis is related to specific forms of learning and memory Chuang, 2010; Curlik and Shors, 2010; Deng et al., 2010; Zhao et al., 2008) , many studies addressed whether changes in neurogenesis are correlated with the progression of AD pathology. The mechanisms and modulation of adult neurogenesis and the potential significance in memory, depression, and neurodegenerative disorders such as AD and Parkinson's disease, have been extensively reviewed before (Lazarov and Marr, 2010; Waldau and Shetty, 2008; Zhao et al., 2008) . Most of the studies on neurogenesis in AD models were carried out in plaque-bearing APP or APP-PS1 transgenic mice (Haughey et al., 2002b; Heo et al., 2007; Waldau and Shetty, 2008) . Following a BrdU pulse-chase approach in combination with double staining for markers of different stages of proliferation and differentiation (e.g. Ki-67, doublecortin), proliferation rate, survival of newborn cells and their differentiation were studied. The major trend of these studies, performed almost exclusively in the SGZ, is that proliferation is increased prior to plaque deposition, and then followed by a decline of proliferation and of long-term survival of newborn cells at stages with a high plaque-load Chuang, 2010; Donovan et al., 2006; Kuhn et al., 2007; Rodriguez et al., 2008; Verret et al., 2007) . As the focus of this review is on the effects of PSEN on neurogenesis (for an overview of neurogenesis in PSEN FAD mice, see Box 1), studies in APP and APP-PS FAD mice (reviewed recently by Marlatt and Lucassen, 2010) will not be further discussed here.
Psen1 is expressed primarily in mature neurons and in a large fraction of the BrdU-positive progenitors (24 h after the last BrdU injection) in the SGZ implying a possible role in neurogenesis in adult brain (Wen et al., 2002a) . In AD brain, PSEN1 was downregulated in neurons but increased in reactive astrocytes, indicating that plaque-associated changes such as inflammation and astrogliosis may affect PSEN expression patterns Takami et al., 1997; Weggen et al., 1998) . The absence of plaques in PSEN FAD models allows a study on neurogenesis not confounded by plaques. In view of the fact that AD, FAD and neurogenesis all have an age-dependent component, one would expect that the effects of PSEN FAD mutations on neurogenesis were investigated in young as well as in older animals, but only a single study addresses this issue in 18-20 month old PS1-P264L/KI mice (Zhang et al., 2007) , whereas all other studies were performed in the hippocampal SGZ (Chevallier et al., 2005; Choi et al., 2008; Wang et al., 2004; Wen et al., 2002b Wen et al., , 2004 or SVZ (Veeraraghavalu et al., 2010 ) of mice just 2-3 month old. A comparison of quantitative studies on proliferation and differentiation is thus hampered not only by the different FAD mutation-promoter combinations used, but foremost by methodological differences such as housing conditions, age, BrdU-application paradigms, survival period and markers employed (Elder et al., 2010b) .
In PS1-P117L mice a consistent finding was that the fraction of surviving BrdU-positive cells 4 weeks later was reduced in PS1-P117L compared to PS1-wild-type mice, indicating a reduced survival of newborn neuronal cells (Wen et al., 2002b (Wen et al., , 2004 . The same mutation results in a significant decrease in neurogenesis from isolated embryonic progenitor cells (Eder-Colli et al., 2009) . Evidence for an impaired proliferation was presented for PS1-M146V/KI and in old PS1-P264L/KI mice (Zhang et al., 2007) . In PS1-A246E mice an increased proliferation was accompanied by a compensatory reduction in the survival of the newborn cells (Chevallier et al., 2005) . The FAD lines PS1-M146L and PS1DE9 showed impaired proliferation after enriched environmental housing. Two weeks after BrdU injection, the fraction of BrdU-immunoreactive cells that expressed DCX, b-III tubulin or NeuN was diminished, indicative of a reduced differentiation into neurons. The combination of a reduced proliferation and reduced differentiation resulted in 2-3-fold reduction in the absolute number of new neurons in the FAD lines. Yet, the proliferation of hippocampal NPCs in culture did not differ between the lines, indicating that alterations in vivo are regulated by cells other than the proliferating cells . On the other hand, in PS1DE9 SVZ-derived NPC cultures, reduced selfrenewing capacity and altered differentiation seem to be regulated in a cell-autonomous manner, possibly due to impaired Notch signaling (Veeraraghavalu et al., 2010) . In summary, in the different PSEN FAD models, neurogenesis seems to be impaired at the level of proliferation and survival of the newborn cells (see also Box 1). The impact of these changes in neurogenesis seems to be minor in terms of cognitive performance. In contrast to the behavioral changes in bigenic or trigenic AD mouse models, PSEN FAD mice show either no detectable changes or only mild deficits with reports being inconsistent between the different PSEN FAD lines (Elder et al., 2010b; Huang et al., 2003; Janus et 
Box 1. Effects of PSEN1 FAD mutations on hippocampal neurogenesis in adult brain
In 2-month old transgenic mice with PS1-P117L driven by the neuron specific promoter NSE, neurogenesis was studied 1 day after the last of 12 daily BrdU injections. The number of BrdU-positive cells in de SGZ was not different between PS1-wild-type compared to PS1-P117L but decreased to non-transgenic mice (Wen et al., 2002b) . This result could not be reproduced in a second study by the same group (Wen et al., 2004) . A consistent finding was that the fraction of surviving BrdUpositive cells 4 weeks later was reduced in PS1-P117L compared to PS1-wild-type indicating a reduced survival of the newborn cells. The fraction of surviving BrdU-positive cells that were either TOAD-64, b-III tubulin-or calbindin-positive 4 weeks after the last injection, showed no clear differences between the three lines (Wen et al., 2002b (Wen et al., , 2004 . The same mutation results in a significant decrease in neurogenesis from isolated embryonic progenitors (Eder-Colli et al., 2009) . Knock-in PS1-M146V mice displayed, at the young age of 3 months, no changes in synaptic physiology or in long-term synaptic plasticity. BrdU-incorporation was studied 12 h after the last of 8 injections given over a period of 4 days revealing a 25% reduction compared to controls suggesting an impaired proliferation. In both lines, 60-70% of the BrdU-positive cells were NeuN-positive. This is a remarkable high percentage given the short survival time . Neurogenesis was studied in 3 month old PS1-A246E or PS1-wild-type transgenes, under the Thy-1 promoter, both in a Psen1 knockout background. Mice were studied at 1 day or 4 weeks after the last of two BrdU-injections. PS1-A246E mice had 44% more BrdU-positive cells in the SGZ compared to controls. At 4 weeks after labelling, the number of BrdU-immunolabelled cells was the same in all groups while the fraction of BrdU-labelled cells that differentiated into NeuN-positive neurons was similar in all groups. So an increased proliferation is accompanied by a compensating reduction in survival the newborn cells in the PS1-A246E mice (Chevallier et al., 2005) . PS1-P264L/KI mice were studied at the age of 8-9 months and at 18-20 months using doublecortin (DCX) and MCM2 immunostaining. The number of DCX-expressing in the DG showed a minor loss at both ages while the number of MCM2-positive cells, a measure for proliferation, was reduced by $40%, suggesting a loss of proliferative activity but no clear reduction in survival (Zhang et al., 2007) . Choi et al. (2008) published on the effects of mouse prion promoter driven PS1-M146L, PS1DE9, or PS1-wild-type, on hippocampal neurogenesis in 2-3 month old mice. BrdU incorporation was quantified 1 day after a single BrdU injection. No differences in NPC proliferation or neurogenesis were seen in the FAD mutant mice housed under standard conditions. However in an enriched environment, NPC proliferation was lower in M146L or DE9 FAD mutant mice compared to wild-type and fewer neurospheres could be cultured from the hippocampus of the FAD mutants, supporting an impaired proliferation under these conditions. In PSEN1 FAD mice crossed with APP knockout mice no such increase was found indicating the impairment is not due to altered Ab levels. At 2 weeks post-labelling, the fraction of BrdU-immunoreactive cells that expressed DCX, b-III tubulin or NeuN was less in FAD mutants showing a reduced differentiation into neurons. The combination of reduced proliferation and reduced differentiation leads to a 2-3-fold reduction in the absolute number of new neurons the FAD groups. Yet, the proliferation of NPCs in culture did not differ between the lines indicating that alterations in vivo are regulated by cells other than the proliferating cells .
Molecular mechanisms for proliferation and neurogenesis in presenilin FAD models
The molecular mechanisms involved in the PSEN FAD related changes in neurogenesis remain elusive. Preparations of Ab 42 can promote neurogenesis (Lopez-Toledano and Shelanski, 2004; Waldau and Shetty, 2008) and the increased Ab 42 levels may explain increases in proliferation, as observed before (Chevallier et al., 2005) . However, it is likely that PSEN-dependent functions, other than cleavage of APP, are involved as well. In mice, Notch signaling plays an important role in neurogenesis, not only during embryonic development but also in the adult brain (Ables et al., 2010; Breunig et al., 2007) . In Psen knockout models, premature neuronal differentiation of NPCs and impairments in neurogenesis are accompanied by decreased expression of Notch target genes (Donoviel et al., 1999; Handler et al., 2000; Kim and Shen, 2008; Wong et al., 1997) . In NPCs cultured from PSEN FAD PS1DE9 mice, impaired Notch signaling appears to be directly involved in the altered proliferation, differentiation and self-renewal capacity, as these defects can be rescued by the expression of constitutively active NICD (Veeraraghavalu et al., 2010) .
Interestingly, primary cortical neurons of PS1-M146V/KI showed enhanced caffeine-sensitive Ca 2+ stores and an increased ryanodine receptor expression (Smith et al., 2005) . Similar observations have been made in cortical slices of 4-6 week old PS1-M146V/KI mice (Stutzmann et al., 2007) and it can be speculated that this alteration may underlie the increased sensitivity for excitotoxicity in PSEN FAD mice and the reduced survival of newborn cells. Another mechanism that has been put forward to explain effects of PSEN on neurogenesis is the involvement of PSEN1 activity in Wnt signaling. There are substantial data showing that Wnt signaling increases adult neurogenesis in hippocampus and SVZ. By contrast, blockade of Wnt signaling reduces neurogenesis (Adachi et al., 2007; Chevallier et al., 2005; Lie et al., 2005; Qu et al., 2010; Toledo et al., 2008) . PSEN1 is a regulator of free cytosolic bcatenin levels, a key effector of the canonical Wnt signaling pathway. PSEN1 contributes to b-catenin degradation by promoting phosphorylation of b-catenin independent of Wnt stimulation, and loss of Psen leads to overactivation of Wnt signaling and hyperproliferation (Kang et al., 2002; Soriano et al., 2001) . It may thus be hypothesized that proliferation in the SGZ is supported by an active Wnt signaling pathway, resulting, together with a low PSEN activity, in elevated b-catenin levels in neural stem/ progenitor cells.
FAD mutations in PSEN can affect the stability of cytosolic bcatenin, although it is debated whether these mutations lead to an increase or reduction of Wnt signaling (Boonen et al., 2009) . In favor for an upregulation of Wnt signaling, expression of PS1-M146L in mice was found to be correlated with an increase in steady-state levels of endogenous b-catenin, consistent with a partial ''loss-of-function'' phenotype with respect to b-catenin degradation (Kang et al., 1999) . Expression of PS1-A246E in a Psen1À/À background leads to a transient increase in NPC proliferation compared to overexpression of PS1-wild-type. It is however unclear if the observed hyperproliferation can be directly related to elevated b-catenin mediated Wnt signaling (Chevallier et al., 2005) . Alternatively, a PSEN FAD mediated ''gain-offunction'' in stem/progenitor cells will increase b-catenin degradation in proliferating cells in the SGZ, and result in a reduced proliferation and cell survival (Kawamura et al., 2001) . Indeed, expression of PS1-M146L inhibited Wnt-3A-induced accumulation of b-catenin, thereby reducing Wnt signaling (Kawamura et al., 2001) . Although the data on the effect of PSEN FAD mutations on Wnt signaling are conflicting, it does demonstrate that mutations in PSEN can deregulate Wnt signaling, and through this pathway affect neural proliferation (reviewed by Boonen et al., 2009) . PSEN FAD models recapitulate early stages of AD in which Ab 42 levels are already increased but plaque formation and the associated microglia activation and gliosis has not yet occurred. PSEN FAD mutations lead to decreased hippocampal stem cell proliferation and reduced survival of newborn cells pointing at a role of PSEN in adult neurogenesis. The molecular mechanism responsible for the involvement of PSEN in neurogenesis and its functional consequences in the AD process are as yet not very well delineated.
g-Secretase inhibitor treatment in mice
Given the profound effect of PSEN on NSCs/NPCs and neurogenesis, it is conceivable that the pharmacological inhibition of g-secretase may also affect these processes. In AD transgenic mouse models, various studies have shown a reduction in amyloid load after g-secretase inhibitor treatment (Panza et al., 2010) . However, only limited data are available on behavioral and cognitive effects resulting from inhibitor treatment, e.g. (Comery et al., 2005; Imbimbo et al., 2009; Martone et al., 2009 ). The effect of pharmacological g-secretase inhibition or modulation on neurogenesis is not well studied in wild-type or AD mouse models. One study shows that in 6 month-old APP FAD transgenic mice, decreased numbers of DCX-positive cells in the hippocampal DG can be partially restored by the treatment of these mice with the NSAIDderivative CHF5074 . This compound modulates g-secretase activity to shift from Ab 42 cleavage to less toxic forms of Ab, without inducing Notch-related toxicity (Imbimbo et al., 2007) . Administration of this g-secretase modulator also restores the cortical synaptophysin loss, observed in vehicle-treated FAD transgenic mice, to wild-type levels ).
In humans it was shown that a g-secretase inhibitor developed by Eli Lilly (LY450139) was effective in decreasing the production of Ab (Bateman et al., 2009 ). In August 2010, phase III clinical trials using this same g-secretase inhibitor semagacestat (the IDENTITY trials by Eli Lilly) were halted due to adverse side effects of the treatment. Semagacestat did not slow down disease progression and cognitive decline progressed even faster in mild-to-moderate AD patients treated with semagacestat than in the placebo-treated control group. In addition, semagacestat increased the risk of skin cancer (Extance, 2010) . The underlying cause for the outcome of this trial is not yet known. Administration of g-secretase inhibitors in wild-type mice, including the inhibitor used in the IDENTITY trials, induced an APP-dependent reduction in cortical dendritic spine density (Bittner et al., 2009 ). This toxic effect on synapses might also contribute to the increased cognitive deterioration.
Another possible explanation may lie in the effect of this gsecretase inhibitor on substrates other than APP, including Notch. Therefore, the development of ''Notch-sparing'' inhibitors is a promising approach for future drug development (Kounnas et al., 2010) . Also, developing compounds which selectively target a specific subunit isoform of the g-secretase complex could circumvent the non-selective inhibition.
In a knockout mouse model, which does not express the Aph-1B isoform of the Aph-1 g-secretase protein subunit, amyloid pathology is decreased without Notch-related side effects (Serneels et al., 2009 ). Novel selective Aph-1B/g-secretase modulating compounds could thus provide a mechanism to lower Ab levels in the brain without interfering with the Notch pathway . Also, the recent discovery of a g-secretase activating protein (GSAP), which interacts with APP and g-secretase to selectively increase Ab, provides a new drug target for AD which does not affect Notch signaling (He et al., 2010) .
Other animal models of presenilin
Besides the Psen mouse models of AD, additional model organisms have provided valuable information on the physiological role of PSEN and on neuropathological effects of PSEN FAD mutations. The PSEN gene is highly conserved during evolution, which allows to study effects of PSEN FAD mutations in more simple organisms, like C. elegans and Drosophila. In C. elegans, human PSEN1 and PSEN2 can functionally replace the C. elegans PSEN homologue SEL-12, whereas human PSEN1 FAD mutant proteins are less active in this respect. These experiments have shown that C. elegans is a suitable model system to study presenilin function (Levitan et al., 1996) . More recently, an array of PSEN FAD mutant Drosophila transgenic lines have been developed to study these mutants at the genetic and molecular levels and correlate the activity of the mutant proteins to the age of onset of the disease in human (Seidner et al., 2006) .
Presenilin models in zebrafish
Zebrafish is emerging as a powerful vertebrate model organism that is well suited to study developmental processes and genetic interactions related to neurodegenerative disease (Guo, 2009; Sager et al., 2010; Xia, 2010) . The developmental stages of the zebrafish embryo are well characterized, including a detailed description of nervous system development (Kimmel et al., 1995) . Due to their small size, short generation time, rapid development and large numbers of offspring, zebrafish are an attractive and cost-effective model system for human disease (Amsterdam and Hopkins, 2006) . The externally developing zebrafish embryos are transparent, making them suitable for advanced non-invasive liveimaging techniques. In addition, the genetical tractability of zebrafish allows easy manipulation of gene expression. Injection of morpholino antisense-oligonucleotides (MO) blocks the translation initiation or mRNA splicing of a targeted gene, leading to transient functional knockdown of the specified gene. Conversely, transient overexpression of a particular gene can be achieved by the injection of sense mRNA. Also, zebrafish transgenic lines are developed that show sustained expression of a transgene driven by general or tissue specific promoters. In addition, zebrafish is unique as vertebrate model to be amendable for forward and reverse genetic screens, as well as high-throughput chemical screening (Beis and Stainier, 2006; Lieschke and Currie, 2007) .
Over the last decade, zebrafish have been used for the study of Psen and its role in neurogenesis during development. The role of Psen in adult neurogenesis in zebrafish is not yet well understood. The adult zebrafish brain has a high regenerative capacity and proliferation and neurogenesis are continuously taking place in well-defined neurogenic niches (Adolf et al., 2006; Grandel et al., 2006; Zupanc, 2001) . Recent results show that in the zebrafish telencephalon, the majority of the radial glia cells are quiescent progenitors, and the level of Notch activity regulates the balance between the quiescent and dividing state of these cells. Inhibition of Notch signaling reinitiates the radial glia cells to divide and differentiate into neurons (Chapouton et al., 2010) . These data further underscore the role of Notch signaling in adult neurogenesis, also in a non-mammalian model, and it is conceivable that Psen plays a role herein.
As zebrafish shows high genome conservation with human, it is not surprising that many components of the g-secretase signaling pathway have been identified in zebrafish. The human PSEN1 and PSEN2 genes both have orthologues in zebrafish, psen1 and psen2 respectively (Groth et al., 2002; Leimer et al., 1999) . Also the other components making up the g-secretase complex, Aph-1, Pen-2 and nicastrin have been identified in zebrafish Sager et al., 2010) . Two homologues of the human APP gene are described in zebrafish, appa and appb (Musa et al., 2001) , that show $70% homology to human APP 695 on the amino acid level (Lee and Cole, 2007) . The Ab-encoding region, as well as the transmembrane domain of human APP, is well conserved in zebrafish, and the C-terminal region shows a high similarity between zebrafish and human. Similar to human PSEN1, zebrafish Psen1 is a membrane spanning protein. The two transmembrane aspartic acid residues making up the catalytic site of human PSEN are conserved in zebrafish. psen1 mRNA is expressed maternally and ubiquitously throughout the embryo during development, although the cellular subtype in which Psen1 is expressed has not been studied further in vivo. In vitro, zebrafish Psen1 is able to replace human PSEN1 and is very efficient in generating Ab 42 from APP containing the Swedish FAD mutation. The full-length protein is rapidly turned over and a minor percentage is endogenously cleaved into stable NTFs and CTFs (Leimer et al., 1999) . In the zebrafish embryo, expression of the CTF increases during development, whereas expression of the Psen1 holoprotein is stable (Nornes et al., 2003) .
The zebrafish orthologue of human PSEN2 (zebrafish psen2) is a transmembrane protein showing a high primary structure conservation with human PSEN2 and is also endoproteolytically processed into an NTF and a CTF. Similar to psen1, psen2 transcripts are expressed ubiquitously during embryogenesis and are present at relatively high levels in neural tissue at 24 h post fertilization (hpf). Zebrafish psen2 mRNA is maternally inherited as it is present before the onset of zygotic transcription. However, Psen2 protein could not be detected at these stages, in contrast to Psen1 protein. Psen2 protein is expressed from 6 h onwards starting at early gastrulation (Groth et al., 2002) . Overexpression of psen2 mRNA induced increased levels of psen2 holoprotein expression, but not of Psen2 NTF. In addition, increasing Psen2 levels does not affect the transcription of psen1 (Nornes et al., 2003) .
When Psen1 activity is reduced in zebrafish embryos by injecting fertilized eggs with a Psen1 translational blocking MO, a phenotype arises that resembles the mouse Psen1À/À phenotype. An overview of the phenotype of zebrafish embryos injected with Psen1 and/or Psen2 MOs is given in Table 2 . Psen1 CTF levels are greatly reduced after MO injection, whereas full-length protein and the high molecular weight complexes containing Psen are not affected by the MO injection. In Psen1À/À mice, mild defects in somite formation are found, reminiscent of Notch signaling defects (Shen et al., 1997; Wong et al., 1997) . Also in Psen1 MO-injected embryos, the expression pattern of Notch target gene hairy-related 1 (her1) is disrupted during active somitogenesis, indicating reduced Notch signaling due to loss of Psen1 activity. Her1 is the zebrafish orthologue of human HES7. In addition, myoD expression is altered, also indicating defects in somite formation (Nornes et al., 2003) . Injection of Psen1 MO, as well as of combined Psen1 and Psen2 MO, results in the loss of Notch target gene her6 (orthologue of human HES1) expression and increased expression of neurogenin1 (ngn1) mRNA , a marker for NPCs, further indicative of reduced Notch signaling. The observed somite defects are less severe than in zebrafish mutants that lack Notch signaling, suggesting that as in mice, Psen2 activity can partially compensate for the loss of activity of Psen1.
In some cases of FAD and sporadic AD, aberrant splicing of PSEN is implicated in disease progression. Using specific splice-acceptor site-directed MOs, the effects of interfering with Psen splicing could be well studied in zebrafish embryos. Loss of Psen1 protein induced by injecting Psen1 translational MOs, or by inducing aberrant splicing after exon 6, caused an unexpected upregulation of psen1 transcription, independent of g-secretase activity.
Although the MO interfering with splicing of exon 8 showed only limited effects, at 48 hpf a phenotype resembling Notch phenotype was observed, including hydrocephalus. Psen1 translational MO and Psen1 exon7 splice acceptor MO exerted similar effects. As the phenotypes of translational and splice MOs are comparable, aberrant splicing of Psen1 apparently leads to loss-of-function of Psen1. Also, this is achieved by a dominant negative mechanism, as limited levels of aberrant transcripts are sufficient to exert the effect, which is possibly mediated by the production of truncated peptides after aberrant splicing. The truncated Psen1 derived by aberrant splicing not only reduces Psen1 activity, but also can interfere with Psen2 activity. These truncated fragments might thus be able to prevent the NTF-CTF heterodimer formation and as such block formation of the active g-secretase complex (Nornes et al., 2008) . Abnormal splicing occurs frequently in aged cells (Meshorer and Soreq, 2002) , providing a possible mechanism by which decreased PSEN1 activity through aberrant splicing of the transcript might contribute to pathological changes underlying sporadic AD (Nornes et al., 2008) .
Interfering with exon 8 splicing of zebrafish Psen1 or Psen2 results in phenotypic effects, including hydrocephalus and reduced pigmentation. Gene expression analysis of embryos injected with Psen1 or Psen2 splice MO revealed that of the 100 genes showing highest regulation, twelve genes were commonly regulated between the two conditions, including cyclin G1, prosaposin, cathepsin Lb, heat shock protein 70 and hatching enzyme (all upregulated). Indeed, Psen1 or Psen2 exon8 MO injection resulted in increased and ectopic cyclin G1 (ccng1) mRNA expression. However, the hydrocephalus and pigmentation phenotype resulting from Psen1 splice MO injection could not be rescued by coinjecting ccng1 MO, indicating that this phenotype is not solely caused by ccng1 ). This study shows zebrafish models can be used to find novel genes affected by Psen1 loss-offunction. Future studies should investigate if there is correlation between regulation of these genes and possible AD mechanisms. For example, CCNG1 protein is upregulated in the affected brain areas in human AD (Jordan-Sciutto et al., 1999) and MCI (Sultana and Butterfield, 2007) . As such, functional analysis of ccng1 in zebrafish might contribute to understanding the role of this protein in AD pathogenesis .
In mice, loss of Psen2 activity results in a very mild phenotype, showing subtle pulmonary fibrosis and hemorrhage during aging (Herreman et al., 1999) . In zebrafish, reducing Psen2 expression by MO injection gives rise to a phenotype resembling loss of Psen1 activity, including enlarged brain ventricles and reduced pigmentation. ngn1 expression is regulated by the Notch signaling pathway as injection of Psen2 translational MO increases ngn1 expression in the spinal cord due to decreased Notch signaling. Psen1 or Psen 2 MO injection increases the number of Rohon-Beard dorsal sensory neurons, and results in a decreased number of neural crest cells. In a second type of dorsal neuron, the dorsal longitudinal ascending interneuron (DoLA), a specific effect of Psen2 loss-of-function is observed as the number of DoLA neurons is increased after injection of Psen2 MO, but is not affected by decreased activity of Psen1. A combined decrease of Psen1 and Psen2 activity partially reverses the effect of Psen2 MO, suggesting an opposing effect of Psen1 and Psen2. This points to non-redundant roles for both presenilins in zebrafish development ).
Additional g-secretase components Pen-2 (psenen, previous name pen2) and Aph-1 (aph1b) have been identified in zebrafish. Like Psen1, both these transcripts are maternally transmitted and are ubiquitously expressed in the zebrafish embryo at 12 hpf, showing a more confined pattern at later stages. In embryos injected with Aph-1 MO or Pen-2 MO, the levels of Psen1 CTF decreased, indicating that also in zebrafish, Aph-1 and Pen-2 are necessary for the stabilization of Psen1 fragments. Knockdown of Pen-2 by MO results in a severe phenotype, including the appearance of opaque regions throughout the embryo, indicating cell death. Indeed, a clear reduction of islet-1 positive neurons in the brain and along the spinal cord was found, as well as a loss of trigeminal and Rohon-Beard neurons. As part of the g-secretase complex, Aph-1 and Pen-2 are involved in Notch signaling, as exemplified by decreased expression of Notch target gene her6 and increased ngn1 expression upon knockdown of either protein .
The decrease in neurons in the spinal cord observed in the Pen-2 MO injected embryos can be attributed to p53-dependent apoptosis. This increased apoptosis is not seen with Psen1 MO or with DAPT treatment that inhibits all g-secretase activity.
Therefore, the increased apoptosis might be related to, but is not solely attributable to, loss of g-secretase . Additional research showed that the cytosolic loop of Pen-2 harbors the anti-apoptotic activity as Pen-2 without this loop region was not capable of rescuing the apoptotic phenotype seen upon Pen-2 MO injection. Using this zebrafish model of Pen-2 knockdown, the novel anti-apoptotic role of Pen-2 was discovered as well as an unconventional pro-apoptotic activation of NFkB . Besides Psen, Aph-1 and Pen-2, gsecretase also contains nicastrin, which is required for secretase activity through substrate recognition (Shah et al., 2005) , although it may also function to stabilize the complex and does not appear to be required for enzyme activity . In zebrafish, the Campbell et al. (2006) and Nornes et al. (2008 Nornes et al. ( , 2009 nicastrin gene has been sequenced and the protein shows 54% identity with human nicastrin (Sager et al., 2010) , however the function of nicastrin in zebrafish has not been further studied yet.
Zebrafish as a model to screen for potential Alzheimer's disease drugs
One of the potential drug treatments for AD is to reduce the levels of Ab production in the brain by inhibiting g-secretase activity. However, an unwanted side effect of g-secretase inhibitor treatment is its detrimental effect on other g-secretase substrates besides APP, like Notch (Bergmans and De Strooper, 2010) . As mentioned previously, zebrafish is an excellent in vivo model to study effects of many different compounds in a high-throughput manner using simple phenotypic readouts. In an initial study by Geling et al., the phenotypic effects of the known g-secretase inhibitor DAPT were assessed. DAPT treatment e.g. results in impaired somite formation, resembling Notch phenotypes in zebrafish. Also the number of ngn1 positive cells increased, indicative of a neurogenic phenotype. This study provided the validation of zebrafish as a model to find g-secretase lowering drugs, with somitogenesis and neurogenesis readouts being present already at 24 hpf (Geling et al., 2002) . Subsequent studies have assessed the effects of known and novel g-secretase inhibitors on zebrafish phenotypes, using the expression of the Notch downstream target gene her6 as readout. DAPT reduced her6 expression in a dose-dependent manner and induced an increase in tail curvature at 48 hpf, whereas gsecretase inhibitor compound E displayed a weaker phenotype . Also GSI A and GSI 18, both potent g-secretase inhibitors, induced a Notch-like phenotype in zebrafish embryos, where GSI 18 caused the stronger phenotype . As yet, no large scale screening for g-secretase activity lowering agents has been performed in zebrafish.
Concluding remarks
The versatile protein PSEN is involved in many cellular processes, including cleavage of substrate proteins like Notch and APP. PSEN also plays a role in e.g. cell adhesion, calcium regulation and protein trafficking. In relation to AD, the most wellcharacterized role of PSEN is its function as part of the g-secretase complex, which mediates intra-membranous cleavage of APP to generate Ab peptides. In addition, PSEN is essential for NPC maintenance in the developing brain and is involved in neurogenesis. By the use of mouse models with (conditional) knockout of Psen or transgenic models overexpressing (FAD) PSEN, valuable insights are obtained into the role of PSEN in physiology and neurodegenerative disease.
Over the last years, also zebrafish has emerged as an attractive model for AD-related research. Transient overexpression of proteins can be easily established by mRNA injections and knockdown of proteins by MO injections into fertilized one-to four-cell zebrafish eggs. By establishing transgenic lines stably expressing protein associated with AD, the etiology of Alzheimerrelated pathology can be monitored real-time in vivo, and large scale drug screening can be performed for disease modifying agents, as recently shown for a zebrafish transgenic model for tauopathies (Paquet et al., 2009 ). The development of novel transgenic zebrafish lines expressing human APP, PSEN with or without FAD mutations, could help to further elucidate the role of PSEN/g-secretase in AD-related pathogenesis, with special emphasis on the analysis of neuronal development and on drug targets aimed at reducing Ab generation mediated by g-secretase activity. As zebrafish is a suitable model for forward and reverse genetics, also novel modifiers of the induced phenotype can be identified to serve as an attractive starting point in the design of future AD treatment strategies.
